These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 20531312)
21. Consultation corner. Prostate cancer vaccine offers new direction. Drake C Johns Hopkins Med Lett Health After 50; 2010 Sep; 22(7):6-7. PubMed ID: 20848753 [No Abstract] [Full Text] [Related]
27. Maine law requires drug companies to provide clinical trial data. Appell D J Natl Cancer Inst; 2005 Sep; 97(17):1246. PubMed ID: 16145043 [No Abstract] [Full Text] [Related]
28. The problem of new uses. Eisenberg RS Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897 [No Abstract] [Full Text] [Related]
29. From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Madan RA; Aragon-Ching JB; Gulley JL; Dahut WL Expert Rev Vaccines; 2011 Jun; 10(6):743-53. PubMed ID: 21692697 [TBL] [Abstract][Full Text] [Related]
30. Food and Drug Administration regulation and evaluation of vaccines. Marshall V; Baylor NW Pediatrics; 2011 May; 127 Suppl 1():S23-30. PubMed ID: 21502242 [TBL] [Abstract][Full Text] [Related]
31. Is Provenge Angst a symbol or symptom of the times? Holcombe DG Am J Manag Care; 2012 May; 18(3 Spec No.):SP108-9. PubMed ID: 22642274 [No Abstract] [Full Text] [Related]
32. Immune-boosting prostate cancer vaccine endorsed by FDA advisors. McBride D ONS Connect; 2007 Jul; 22(7):19. PubMed ID: 17694780 [No Abstract] [Full Text] [Related]
33. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer. McKarney I Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575 [TBL] [Abstract][Full Text] [Related]
35. External influences on protocol design. Spilker B Epilepsy Res Suppl; 1993; 10():115-24. PubMed ID: 8251087 [No Abstract] [Full Text] [Related]
36. Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS. Kim J; Ross JS; Kapczynski A JAMA; 2018 Jan; 319(1):21-22. PubMed ID: 29117365 [No Abstract] [Full Text] [Related]
37. Managed care considerations. A new era of advanced prostate cancer management. Muller R Manag Care; 2011 Sep; 20(9 Suppl 5):5. PubMed ID: 22043721 [No Abstract] [Full Text] [Related]
38. What happened to the Provenge (Sipuleucel-T) vaccine for hormone refractory prostate cancer? Moyad MA Urol Nurs; 2007 Jun; 27(3):256-7. PubMed ID: 17674606 [TBL] [Abstract][Full Text] [Related]
39. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. Nabhan C N Engl J Med; 2010 Nov; 363(20):1966-7; author reply 1968. PubMed ID: 21067391 [No Abstract] [Full Text] [Related]
40. Changes at FDA may speed drug approval process and increase off-label use. Reh M J Natl Cancer Inst; 1998 Jun; 90(11):805-7. PubMed ID: 9625166 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]